AbbVievsKura Oncology

ABBV and KURA stock compared: price, dividend, valuation and results, from SEC filings.

AbbVie (ABBV) has a market value of $507B and Kura Oncology (KURA) $642M. Over the last year, with dividends, ABBV moved +27.2% and KURA -35.9%. Dividend yield: ABBV 2.41%, KURA none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$507B

    KURA$642M

    ABBV is 790 times KURA

  • Revenue, 12 months

    ABBV$66.0B

    KURA$79M

    ABBV is 832 times KURA

  • Net income, 12 months

    ABBV$10.3B

    KURA-$293M

  • Operating margin

    ABBV32.2%

    KURA-394.3%

    426.5 points apart

  • ROIC

    ABBV25.7%

    KURA-192.2%

    217.9 points apart

  • P/E

    ABBV49.3

    KURA–

  • Dividend yield

    ABBV2.4%

    KURA0.0%

    2.4 points apart

  • 5-year return

    ABBV+195.8%

    KURA-57.3%

    253.1 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+195.8%

KURA-57.3%

10020030020222023202420252026
Returns by period
PeriodABBVWith dividendsKURAWith dividends
1 year since November 19, 2025+27.2%Price +23.5%-35.9%Price -35.9%
3 years since November 20, 2023+129.9%+32.0% a yearPrice +107.9%-24.0%-8.7% a yearPrice -24.0%
5 years since November 19, 2021+195.8%+24.2% a yearPrice +147.4%-57.3%-15.6% a yearPrice -57.3%
10 years since November 21, 2016+615.6%+21.7% a yearPrice +376.0%+32.0%+2.8% a yearPrice +32.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieKURAKura Oncology

Valuation

ABBVKURA
Valuation
Price$286.82$7.26
Market value$507B$642M
Enterprise value (EV)$577B–
P/E49.3–
P/E, 5-year median57.0–
P/B–35.7
EV/EBIT27.2–
Free cash flow yield3.7%–

Results and growth

ABBVKURA
Results and growth
Revenue, 12 months$66.0B$79M
Net income, 12 months$10.3B-$293M
Free cash flow, 12 months$18.9B-$89M
Earnings per share, 12 months$5.81-$3.30
Revenue growth, year on year8.6%25.2%
Revenue growth a year, past+5.9%over 5 years–
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVKURA
Margins and returns on capital
Gross margin73.7%–
Operating margin32.2%-394.3%
Net margin15.7%-369.3%
ROIC25.7%-192.2%
ROE–-247.8%

Balance sheet

ABBVKURA
Balance sheet
Cash$10.8B$492M
Total debt$80.9B–
Net debt / EBITDA3.2–
Interest cover7.1×-227.1×

Dividends and buybacks

ABBVKURA
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.6%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or KURA

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Kura Oncology?

By market value, AbbVie ($507B) is about 790.3 times Kura Oncology ($642M), at today's prices.

How did ABBV and KURA stock do over the last 10 years?

Since November 21, 2016, ABBV's price moved +376.0% and KURA's +32.0%. With dividends: ABBV +615.6% (+21.7% a year), KURA +32.0% (+2.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or KURA?

The dividend yield at today's price is 2.41% for AbbVie and none for Kura Oncology. Over the last twelve months they paid $6.92 and – per share.

Which has the higher profit margins, AbbVie or Kura Oncology?

Over the last twelve months, the net margin was 15.7% for AbbVie and -369.3% for Kura Oncology, and the operating margin 32.2% and -394.3%. Revenue was $66.0B and $79M.

Which is the better investment, AbbVie or Kura Oncology?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.